Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 692342

Drug Profile

GSK 692342

Alternative Names: 692342; GSK M72; GSK-692342; M72/AS01E; Mtb72F/AS02A; Recombinant-tuberculosis-vaccine-GlaxoSmithKline; SB-692342; Tuberculosis-vaccine-Aeras/GlaxoSmithKline; Tuberculosis-vaccine-GlaxoSmithKline; Tuberculosis-vaccine-Mtb72f/AS02A; Tuberculosis-vaccine-recombinant-fusion-protein-Mtb72f/AS02A

Latest Information Update: 22 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Recombinant fusion proteins; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 16 Nov 2018 Aeras and GlaxoSmithKline completes a phase IIb trial in Healthy volunteers in South Africa, Kenya and Zambia (IM) (NCT01755598)
  • 05 Feb 2018 GSK 692342 is still in phase II trials for Tuberculosis in Kenya, South Africa and Zambia (NCT01755598)
  • 21 Jul 2015 Phase-II development is ongoing in Belgium, Gambia, India, Philippines, Switzerland and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top